1
|
Moran GW, Thapaliya G. The Gut-Brain Axis and Its Role in Controlling Eating Behavior in Intestinal Inflammation. Nutrients 2021; 13:nu13030981. [PMID: 33803651 PMCID: PMC8003054 DOI: 10.3390/nu13030981] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 03/10/2021] [Accepted: 03/16/2021] [Indexed: 12/12/2022] Open
Abstract
Malnutrition represents a major problem in the clinical management of the inflammatory bowel disease (IBD). Presently, our understanding of the cross-link between eating behavior and intestinal inflammation is still in its infancy. Crohn's disease patients with active disease exhibit strong hedonic desires for food and emotional eating patterns possibly to ameliorate feelings of low mood, anxiety, and depression. Impulsivity traits seen in IBD patients may predispose them to palatable food intake as an immediate reward rather than concerns for future health. The upregulation of enteroendocrine cells (EEC) peptide response to food intake has been described in ileal inflammation, which may lead to alterations in gut-brain signaling with implications for appetite and eating behavior. In summary, a complex interplay of gut peptides, psychological, cognitive factors, disease-related symptoms, and inflammatory burden may ultimately govern eating behavior in intestinal inflammation.
Collapse
Affiliation(s)
- Gordon William Moran
- National Institute of Health Research Nottingham Biomedical Research Centre, University of Nottingham, and Nottingham University Hospitals NHS Trust, Nottingham NG7 2UH, UK
- Correspondence:
| | - Gita Thapaliya
- Division of Child & Adolescent Psychiatry, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA;
| |
Collapse
|
2
|
Alard J, Cudennec B, Boutillier D, Peucelle V, Descat A, Decoin R, Kuylle S, Jablaoui A, Rhimi M, Wolowczuk I, Pot B, Tailleux A, Maguin E, Holowacz S, Grangette C. Multiple Selection Criteria for Probiotic Strains with High Potential for Obesity Management. Nutrients 2021; 13:nu13030713. [PMID: 33668212 PMCID: PMC7995962 DOI: 10.3390/nu13030713] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Revised: 02/16/2021] [Accepted: 02/17/2021] [Indexed: 12/25/2022] Open
Abstract
Since alterations of the gut microbiota have been shown to play a major role in obesity, probiotics have attracted attention. Our aim was to identify probiotic candidates for the management of obesity using a combination of in vitro and in vivo approaches. We evaluated in vitro the ability of 23 strains to limit lipid accumulation in adipocytes and to enhance the secretion of satiety-promoting gut peptide in enteroendocrine cells. Following the in vitro screening, selected strains were further investigated in vivo, single, or as mixtures, using a murine model of diet-induced obesity. Strain Bifidobacterium longum PI10 administrated alone and the mixture of B. animalis subsp. lactis LA804 and Lactobacillus gasseri LA806 limited body weight gain and reduced obesity-associated metabolic dysfunction and inflammation. These protective effects were associated with changes in the hypothalamic gene expression of leptin and leptin receptor as well as with changes in the composition of gut microbiota and the profile of bile acids. This study provides crucial clues to identify new potential probiotics as effective therapeutic approaches in the management of obesity, while also providing some insights into their mechanisms of action.
Collapse
Affiliation(s)
- Jeanne Alard
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
| | - Benoit Cudennec
- Université de Lille, UMR-T 1158, BioEcoAgro, F-59000 Lille, France;
| | - Denise Boutillier
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
| | - Véronique Peucelle
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
| | - Amandine Descat
- EA 7365-GRITA-Groupe de Recherche sur les formes Injectables et les Technologies Associées, Université de Lille, CHU Lille, F-59000 Lille, France;
| | - Raphaël Decoin
- Institut Pasteur de Lille, Université deLille, Inserm, CHU Lille, U1011—EGID, F-59000 Lille, France; (R.D.); (A.T.)
| | - Sarah Kuylle
- GENIBIO, Le Pradas, ZI du Couserans, 09190 Lorp-Sentaraille, France;
| | - Amin Jablaoui
- Institut Micalis, INRAE, AgroParisTech, Université Paris-Saclay, F-78350 Jouy-en-Josas, France; (A.J.); (M.R.); (E.M.)
| | - Moez Rhimi
- Institut Micalis, INRAE, AgroParisTech, Université Paris-Saclay, F-78350 Jouy-en-Josas, France; (A.J.); (M.R.); (E.M.)
| | - Isabelle Wolowczuk
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
| | - Bruno Pot
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
| | - Anne Tailleux
- Institut Pasteur de Lille, Université deLille, Inserm, CHU Lille, U1011—EGID, F-59000 Lille, France; (R.D.); (A.T.)
| | - Emmanuelle Maguin
- Institut Micalis, INRAE, AgroParisTech, Université Paris-Saclay, F-78350 Jouy-en-Josas, France; (A.J.); (M.R.); (E.M.)
| | - Sophie Holowacz
- PiLeJe Laboratoire, 37 Quai de Grenelle, 75015 Paris, France;
| | - Corinne Grangette
- U1019—UMR 9017—CIIL—Centre d’Infection et d’Immunité de Lille, Institut Pasteur de Lille, Université de Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France; (J.A.); (D.B.); (V.P.); (I.W.); (B.P.)
- Correspondence: ; Tel.: +33-3208-77392
| |
Collapse
|